Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review
International Journal of Molecular Sciences · 18.05.2023 · 24 (10) · 8926
DOI: 10.3390/ijms24108926 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.05.2023. Verfasst von Hiroshi Toshida und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Juntendo University Shizuoka Hospital, Shizuoka 410-2211, Japan. Hauptthemen laut MEDLINE: Mouth Mucosa, Corneal Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Promotion and Mutual Aid Corporation for Private Schools of Japan.
Abstract (Originalsprache)
The first product in the world for ex vivo cultivated oral mucosal epithelial cell transplantation (COMET) to treat limbal stem cell deficiency (LSCD), named Ocural®, was launched in June 2021 in Japan. COMET was performed on two patients, including the first case in the post-marketing phase of Ocural®. Pathological and immunohistochemical examinations were also carried out using specimens obtained before and after COMET and the spare cell sheet. In case 1, the ocular surface remained free from epithelial defects for approximately six months. In case 2, although defect of the cornea-like epithelia was observed after COMET for one month, it was resolved after the insertion of lacrimal punctal plugs. In case 1, adjuvant treatment was interrupted due to an accident during the second month after COMET, resulting in conjunctival ingrowth and corneal opacity. Eventually, a lamellar keratoplasty was required at six months after COMET. Immunohistochemistry revealed the presence of markers for stem cells (p63, p75), proliferation (Ki-67), and differentiation (Keratin-3, -4, and -13) in both the cornea-like tissue after COMET and a cultivated oral mucosal epithelial cell sheet. In conclusion, Ocural® can be accomplished without major complications, and the stem cells derived from oral mucosa might be successfully engrafted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Juntendo University Shizuoka Hospital, Shizuoka 410-2211, Japan.
- Laboratory of Morphology and Image Analysis, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine, Tokyo 113-0033, Japan.
ORCID-Profile: Hiroshi Toshida
Förderung
- Promotion and Mutual Aid Corporation for Private Schools of Japan
Zitieren
APA
Toshida, H., Kasahara, T., Kiriyama, M., Iwasaki, Y., Sugita, J., Ichikawa, K., Ohta, T., & Miyahara, K. (2023). Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review. International Journal of Molecular Sciences, 24(10), 8926. https://doi.org/10.3390/ijms24108926
Vancouver
Toshida H, Kasahara T, Kiriyama M, Iwasaki Y, Sugita J, Ichikawa K, et al. Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review. International Journal of Molecular Sciences. 2023;24(10):8926. doi:10.3390/ijms24108926
BibTeX
@article{Toshida2023,
author = {Toshida, Hiroshi and Kasahara, Tomoto and Kiriyama, Masamichi and Iwasaki, Yuma and Sugita, Jobu and Ichikawa, Kohei and Ohta, Toshihiko and Miyahara, Katsumi},
title = {Early Clinical Outcomes of the First Commercialized Human Autologous Ex Vivo Cultivated Oral Mucosal Epithelial Cell Transplantation for Limbal Stem Cell Deficiency: Two Case Reports and Literature Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {8926},
doi = {10.3390/ijms24108926}
}
EUVIMED